Skip to main content
. 2019 Feb;95(2):155–168. doi: 10.1124/mol.118.113233

Fig. 6.

Fig. 6.

AM1710 does not precipitate CB1 receptor-mediated cannabinoid withdrawal. Administration of the CB1 antagonist rimonabant (10 mg/kg, i.p.) increased the number of paw tremors (A), headshakes (B), grooming (C), and rearing behaviors (D) in mice chronically treated with Δ9-THC (50 mg/kg per day × 9 days, i.p.). By contrast, AM1710 (10 mg/kg, i.p.) did not induce these CB1 receptor–mediated withdrawal behaviors. n = 6 males, C57BL/6J for each group. ##P < 0.01; ###P < 0.001 vs. vehicle; *P < 0.05; **P < 0.01 vs. AM1710 (two-way mixed ANOVA, followed by Bonferroni post hoc test). First challenge: vehicle challenge; second challenge: rimonabant or AM1710 challenge.